Common Stock

On August 6, 2025, KKR Hawaii Aggregator L.P. entered into a total return swap (the "Swap") with a third-party financial counterparty. On August 12, 2025, the initial hedge period was completed, and the number of notional shares of Common Stock covered by the Swap was set at 1,874,538 shares of Common Stock and the notional price per share was determined to be $66.19.

Pursuant to the Swap, KKR Hawaii Aggregator L.P. has the right to acquire, and the counterparty has the obligation to deliver to KKR Hawaii Aggregator L.P., an aggregate of 1,874,538 shares of Common Stock. Upon such acquisition and settlement of shares of Common Stock, such shares of Common Stock would be directly held by KKR Hawaii Aggregator L.P. KKR Hawaii Aggregator GP LLC is the general partner of KKR Hawaii Aggregator L.P. KKR North America Fund XIII SCSp is the sole member of KKR Hawaii Aggregator GP LLC. KKR Associates North America XIII SCSp is the general partner of KKR North America Fund XIII SCSp. KKR North America XIII S.a r.l. is the general partner of KKR Associates North America XIII SCSp. KKR North America XIII Holdings Limited is the sole shareholder of KKR North America XIII S.a r.l.

KKR Group Partnership L.P. is the sole shareholder of KKR North America XIII Holdings Limited. KKR Group Holdings Corp. is the general partner of KKR Group Partnership L.P. KKR Group Co. Inc. is the sole shareholder of KKR Group Holdings Corp. KKR & Co. Inc. is the sole shareholder of KKR Group Co. Inc. KKR Management LLP is the Series I preferred stockholder of KKR & Co. Inc. Messrs. Henry R. Kravis and George R. Roberts are the founding partners of KKR Management LLP.

Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.

Because no more than 10 reporting persons can file any one Form 4 through the Securities and Exchange Commission's EDGAR system, certain affiliates of the Reporting Persons have filed a separate Form 4.


Common Stock


Class A Common Stock

Class A Common Stock

Reflects the conversion of Class A Common Units ("Class A Units") of Carvana Group, LLC ("Carvana Group") owned directly by Ernest C. Garcia II into shares of Class A Common Stock ("Class A Shares") of the Issuer pursuant to the Exchange Agreement, dated April 27, 2017, by and among the Issuer, Carvana Co. Sub LLC, Carvana Group and the members of Carvana Group (the "Exchange Agreement").

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Ernest C. Garcia II and Elizabeth Joanne Garcia on December 13, 2024.

The prices reported in Column 4 are weighted average prices.  These shares were sold in multiple transactions at prices ranging from $343.84-$344.77, inclusive (weighted average of $344.3296); $344.91-$345.87, inclusive (weighted average of $345.5376); $345.91-$346.90, inclusive (weighted average of $346.3018);$346.91-$347.90, inclusive (weighted average of $347.4381); $347.91-$348.90, inclusive (weighted average of $348.5012); $348.92-$349.91, inclusive (weighted average of $349.3626); $349.92-$350.89, inclusive (weighted average of $350.2334); and $350.94-$351.44, inclusive (weighted average of $351.0997), respectively. The reporting person undertakes to provide to the issuer or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

Reflects the cancellation for no consideration of Class B Common Stock of the Issuer ("Class B Shares") in connection with the conversion of Class A Units into Class A Shares. Following the reported transaction, the remaining Class B Shares are owned directly by Ernest C. Garcia II.

These Class B Shares are owned directly by ECG II SPE, LLC ("E-SPE"), an entity which Mr. Garcia wholly owns and controls.

These Class A Units are owned directly by E-SPE and are exchangeable for 0.8 Class A Shares pursuant to the Exchange Agreement.


Common Stock

Common Stock

The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025.

The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $96.00 to $96.63 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The stock option is fully vested.

/s/ Stephen Vander Stoep, attorney-in-fact for Hunter C. Smith


Common Stock

Common Stock

The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2025.

The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date.

The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

/s/ Stephen Vander Stoep, attorney-in-fact for Christopher Paul German


Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock.


Class A Common Stock

Class A Common Stock

The prices reported in Column 4 are weighted average prices.  These shares were sold in multiple transactions at prices ranging from $335.40-$335.43, inclusive (weighted average of $335.4003); $336.40-$337.36, inclusive (weighted average of $337.1186); $337.40-$338.38, inclusive (weighted average of $337.9644); $338.40-$339.39, inclusive (weighted average of $338.8964); $339.40-$340.39, inclusive (weighted average of $339.8805); $340.40-$341.33, inclusive (weighted average of $340.8558); $341.41-$342.38, inclusive (weighted average of $341.9091); and $342.41-$343.40, inclusive (weighted average of $343.1179), respectively. The reporting person undertakes to provide to the issuer or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

The prices reported in Column 4 are weighted average prices.  These shares were sold in multiple transactions at prices ranging from $343.41-$344.40, inclusive (weighted average of $343.7732); $344.43-$345.38, inclusive (weighted average of $344.8823); $348.00-$348.91, inclusive (weighted average of $348.613); $349.02-$349.50, inclusive (weighted average of $349.3897); $350.02-$351.00, inclusive (weighted average of $350.4327); $351.02-$351.99, inclusive (weighted average of $351.5612); $352.04-$353.025, inclusive (weighted average of $352.5109); $353.08-$354.05, inclusive (weighted average of $353.5931); and $354.08-$354.48, inclusive (weighted average of $354.1745), respectively. The reporting person undertakes to provide to the issuer or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.


Common Stock

The reporting person received 8,221 shares of common stock upon the net exercise of 15,000 stock appreciation rights ("SARs"). A total of 6,779 shares of common stock underlying such SARs were withheld in payment of the exercise price and to satisfy the withholding tax obligation resulting from the exercise.

The SAR vests and becomes exercisable in two equal installments on each of September 2, 2025 and September 2, 2026.


Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock. A portion of the remaining vested shares was deferred by the Reporting Person to a future date.


This transaction was executed in multiple trades at prices ranging from $14.75 USD to $14.81 USD; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes, upon request, to provide to Comstock Holding Companies, Inc. (the "Issuer"), any security holder ofthe Issuer, or the Securities and Exchange Commission, full information regarding the number of shares and prices at which the transaction was effected.


Owned by United Equities Commodities Company

Common Stock, par value $.01

Common Stock, par value $.01

Common Stock, par value $.01

Common Stock, par value $.01

Common Stock, par value $.01

Common Stock, par value $.01

Mr. Katz disclaims beneficial ownership of the securities held by KF Investors LLC, an entity of which Mr. Katz is a managing member, except to the extent of his pecuniary interest therein.

Mr. Katz  disclaims beneficial ownership of the securities held by Momar Corporation, an entity in which Mr. Katz has an ownership interest, except to the extent of his pecuniary interest therein.

Mr. Katz disclaims beneficial ownership of the securities held by United Equities Commodities Company, an entity of which Mr. Katz is a general partner, except to the extent of his pecuniary interest therein.

Mr. Katz disclaims beneficial ownership of the securities held by Marneu Holding Company, an entity of which Mr. Katz is a partner, except to the extent of his pecuniary interest therein.

Mr. Katz disclaims beneficial ownership of the securities held by 111 John Realty Corp., an entity in which Mr. Katz has an ownership interest, except to the extent of his pecuniary interest therein.

These restricted stock units, which convert into common stock on a one-for-one basis, vest on the day immediately preceding the Company's 2026 annual meeting of shareholders, except as otherwise provided in the award notice.

Each share of phantom stock represents a right to receive one share of common stock and becomes payable at the election of Mr. Katz in the year following the year of his separation from service as a director in either a single lump sum payment or in a maximum of ten annual installments.

This option has fully vested as of the date of this report.

/s/ Roger W. Byrd, Attorney-in-Fact for Philippe D. Katz


Common stock, par value $.01

Common Stock, par value $.01

Common Stock, par value $.01

Common Stock, par value $.01

Common Stock, par value $.01

Common Stock, par value $.01

Common Stock, par value $.01

Common Stock, par value $.01

Common Stock, par value $.01

Common Stock, par value $.01

Common Stock, par value $.01

Common Stock, par value $.01

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.565 to $5.92, inclusive. Mr. Continenza undertakes to provide Eastman Kodak Company (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

These restricted stock units, which convert into common stock on a one-for-one basis, will vest on 2/26/2026.

These restricted stock units, which convert into common stock on a one-for-one basis, will vest in substantially equal installments on each of 11/29/2025, 11/29/2026 and 11/29/2027.

These restricted stock units, which convert into common stock on a one-for-one basis, will vest in substantially equal installments on each of 11/29/2025 and 11/29/2026.

Each share of phantom stock represents a right to receive one share of common stock and becomes payable at the election of Mr. Continenza in the year following the year of his separation from service as a director in either a single lump sum payment or in a maximum of ten annual installments.

This option is fully vested as of the date of this report.

/s/ Roger W. Byrd, Attorney-in-Fact for James V. Continenza


The price reported in Column 4 is the weighted average price.  These shares were sold in multiple transactions at prices ranging from $262.29 to $263.28, inclusive.  The reporting person undertakes to provide to the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

The price reported in Column 4 is the weighted average price.  These shares were sold in multiple transactions at prices ranging from $263.34 to $263.81, inclusive.  The reporting person undertakes to provide to the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

The price reported in Column 4 is the weighted average price.  These shares were sold in multiple transactions at prices ranging from $264.50 to $265.46, inclusive.  The reporting person undertakes to provide to the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

The price reported in Column 4 is the weighted average price.  These shares were sold in multiple transactions at prices ranging from $265.50 to $266.17, inclusive.  The reporting person undertakes to provide to the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

The price reported in Column 4 is the weighted average price.  These shares were sold in multiple transactions at prices ranging from $263.48 to $264.05, inclusive.  The reporting person undertakes to provide to the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

The price reported in Column 4 is the weighted average price.  These shares were sold in multiple transactions at prices ranging from $264.84 to $265.68, inclusive.  The reporting person undertakes to provide to the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

The price reported in Column 4 is the weighted average price.  These shares were sold in multiple transactions at prices ranging from $266.33 to $267.21, inclusive.  The reporting person undertakes to provide to the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

The price reported in Column 4 is the weighted average price.  These shares were sold in multiple transactions at prices ranging from $267.33 to $267.61, inclusive.  The reporting person undertakes to provide to the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

The price reported in Column 4 is the weighted average price.  These shares were sold in multiple transactions at prices ranging from $265.68 to $266.67, inclusive.  The reporting person undertakes to provide to the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

The price reported in Column 4 is the weighted average price.  These shares were sold in multiple transactions at prices ranging from $266.69 to $267.16, inclusive.  The reporting person undertakes to provide to the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Thomas C. Indelicarto by Power of Attorney for D. James Bidzos


By: /s/ Eric Verity Attorney In Fact For: Gagan Jain


The price in Column 4 is a weighted average price.  The prices actually ranged from $10.8500 to $10.9600.  The reporting person has provided to the issuer, and will provide to any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.

The price in Column 4 is a weighted average price.  The prices actually ranged from $10.6600 to $10.7700.  The reporting person has provided to the issuer, and will provide to any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.

/s/ Teresa M. Nilsen, Attorney-in-Fact for Thomas L. Seavey


Class A Common Stock

Class A Common Stock

Class A Common Stock

Class A Common Stock

Includes shares, RSUs and DSUs.

The option award exercised in this transaction was fully vested on the transaction date.

The stock option grant provides that the options vest and become exercisable one-fourth per year, commencing March 3, 2023.

The stock option grant provides that the options vest and become exercisable one-fourth per year, commencing March 15, 2023.

The stock option grant provides that the options vest and become exercisable one-fourth per year, commencing March 15, 2024.

/s/ Robert M. Wolfe, as attorney-in-fact


Common Stock

Common Stock

Common Stock

At the effective time of the merger (the "Effective Time") between SunLink Health Systems, Inc. ("SunLink") and Regional Health Properties, Inc. ("Regional"), each five shares of Common Stock, no par value per share, of SunLink held by the Reporting Person prior to the Effective Time were converted into the right to receive (i) 1.1330 shares of Common Stock, no par value per share, of Regional, and (ii) one share of Series D 8% Cumulative Convertible Redeemable Participating Preferred Shares, no par value per share, of Regional.

This option was terminated in the merger.

M. Timothy Elder, pursuant to a power of attorney


Class A Common Stock

Class A Common Stock

These shares of Class A common stock reflect the settlement, on August 12, 2025, of restricted stock units ("RSUs") granted to the Reporting Person pursuant to the 2021 Equity Incentive Plan, each of which was converted into a share of the Issuer's Class A common stock on a 1-for-1 basis.

Shares withheld to pay taxes applicable to the settlement of the RSUs previously awarded to the Reporting Person to which footnote (2) refers.

Each RSU represents a contingent right to receive one share of the Issuer's Class A common stock, subject to the Reporting Person's continued status as a service provider to the Issuer.

All remaining 329 RSUs settled on the transaction date.

Not applicable.

25,144 RSUs settled on the transaction date. The remaining 100,580 RSUs vests as to 1/12th of the total award of 301,724 RSUs quarterly in eight equal installments on the 19th of each August, November, February and May thereafter.

These RSUs do not expire; they either vest or are cancelled prior to the vesting date.

/s/ Heather Flores-Ricks, Attorney-in-Fact for David Arroyo


Class A Common Stock

Class A Common Stock

Class A Common Stock

Class A Common Stock

Shares withheld to pay taxes applicable to the settlement of the RSUs previously awarded to the Reporting Person to which footnote (1) refers.

58,594 RSUs settled on August 12, 2025. The remaining 58,593 RSUs vest ratably as to 1/8 of the total award of 468,750 on October 1, 2025.

The remaining 789 RSUs settled on the transaction date.

Not applicable.

1,667 RSUs settled on the transaction date. The remaining 6,668 RSUs vests as to 1/12 of the total award quarterly in eight equal installments on the 19th of each August, November, February and May thereafter.

The remaining 287 RSUs settled on the transaction date.

/s/ Heather Flores-Ricks, Attorney-in-Fact for Matthew Omer


Restricted Stock Units (MSPP Purchased Award)

Common Stock

Restricted Stock Units (MSPP Matching Award)

Common Stock

Fair market value of Intuit Inc. common stock on the trading day immediately preceding the date of reported transaction.

Restricted stock units (MSPP Purchased Award) are fully vested upon grant; however, settlement occurs upon the earlier of termination of employment or three years from grant date.

Represents settlement date for restricted stock units (MSPP Purchased Award). Restricted stock units do not expire; they either vest or are canceled prior to vesting date.

Represents vesting and settlement date for restricted stock units (MSPP Matching Award).

Reporting person was awarded the restricted stock units (MSPP Matching Award) in connection with voluntary participation in a management stock purchase program (MSPP).


Common Stock

The Restricted Stock Units shall vest on the earlier of (i) May 21, 2026 or (ii) if the reporting person does not stand for re-election as a director of the Company, the date of the regular meeting of the Company's stockholders held in the calendar year subsequent to the grant date; provided that, in either case, the reporting person remains in continuous Service through such vesting date.

Restricted stock unit award expires upon reporting person's termination of service.


NEA Partners 15, L.P. ("NEA Partners 15") made a pro rata distribution for no consideration of shares of Common Stock of the Issuer to its limited partners on August 12, 2025. The Reporting Person received 1,586 shares of Common Stock of the Issuer in the distribution by NEA Partners 15 on August 12, 2025.

The Ali Behbahani Revocable Trust Dated June 26, 2015 (the "Behbahani Trust") received 2,621 shares of Common Stock of the Issuer in the distribution by NEA Partners 15 on August 12, 2025.

The Reporting Person is a trustee of the Behbahani Trust, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the 1934 Act, as amended, or otherwise of such portion of the securities held by the Behbahani Trust in which the Reporting Person has no pecuniary interest.


Common Stock

Common Stock


Eugene E. Burleson Family Trust; Spouse as Trustee

Common Stock

At the effective time of the merger (the "Effective Time") between SunLink Health Systems, Inc. ("SunLink") and Regional Health Properties, Inc. ("Regional"), each five shares of Common Stock, no par value per share, of SunLink held by the Reporting Person prior to the Effective Time were converted into the right to receive (i) 1.1330 shares of Common Stock, no par value per share, of Regional, and (ii) one share of Series D 8% Cumulative Convertible Redeemable Participating Preferred Shares, no par value per share, of Regional.

This option was terminated in the merger.


The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024.

The transaction was executed in multiple trades at prices ranging from $254.3100 to $255.2741. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.

The transaction was executed in multiple trades at prices ranging from $255.3318 to $256.2950. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.

The transaction was executed in multiple trades at prices ranging from $256.3982 to $257.3950. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.

The transaction was executed in multiple trades at prices ranging from $257.4000 to $258.3600. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.

The transaction was executed in multiple trades at prices ranging from $258.4000 to $258.9200. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.

The transaction was executed in multiple trades at prices ranging from $257.3200 to $258.2600. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.

The transaction was executed in multiple trades at prices ranging from $258.3700 to $259.3600. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.

The transaction was executed in multiple trades at prices ranging from $259.3900 to $260.3450. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.

The transaction was executed in multiple trades at prices ranging from $260.5750 to $261.0300. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.

The transaction was executed in multiple trades at prices ranging from $260.0500 to $260.6686. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.

The shares are held in grantor retained annuity trusts for the benefit of the reporting person and his children. The reporting person serves as trustee of the grantor retained annuity trusts.

The shares are held in trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts.

/s/ Kathleen Peacock, by power of attorney


Common Stock

Common Stock

Fair market value of Intuit Inc. common stock on the trading day immediately preceding the date of reported transaction.

Restricted stock units (MSPP Purchased Award) are fully vested upon grant; however, settlement occurs upon the earlier of termination of employment or three years from grant date.

Represents settlement date for restricted stock units (MSPP Purchased Award). Restricted stock units do not expire; they either vest or are canceled prior to vesting date.

Represents vesting and settlement date for restricted stock units (MSPP Matching Award).

Reporting person was awarded the restricted stock units (MSPP Matching Award) in connection with voluntary participation in a management stock purchase program (MSPP).


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.

With tandem dividend equivalent rights and tax withholding rights.

Includes 549 dividend equivalent units that had accrued on the restricted stock units.

The restricted stock units were granted on August 12, 2022 and fully vested (including the related dividend equivalent units) on August 12, 2025.

With tandem net exercise and tax withholding rights.

The option vests in three equal installments on August 12, 2026, 2027 and 2028, subject to Ms. Thuerk's continued employment with the Company on the applicable vesting date.

The restricted stock units will vest in three equal installments on August 12, 2026, 2027 and 2028, subject to Ms. Thuerk's continued employment with the Company on the applicable vesting date.

The option vests in two equal installments on August 12, 2026 and 2027, subject to Ms. Thuerk's continued employment with the Company on the applicable vesting date.

The restricted stock units will vest in two equal installments on August 12, 2026 and 2027, subject to Ms. Thuerk's continued employment with the Company on the applicable vesting date.


BERKOWITZ BRUCE R

C/O FAIRHOLME CAPITAL MANAGEMENT, L.L.C.

The reported transactions were in securities held by The Fairholme Fund, a series of Fairholme Funds, Inc. (the "Fairholme Fund"). The securities may be deemed to be beneficially owned by Mr. Bruce R. Berkowitz ("Mr. Berkowitz") because he controls the sole member of Fairholme Capital Management, LLC ("Fairholme"), which may be deemed to have beneficial ownership of the securities because Fairholme serves as the investment manager to the Fairholme Fund. Mr. Berkowitz and Fairholme disclaim beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that Mr. Berkowitz and Fairholme are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.

The reported securities are directly owned by Mr. Berkowitz.


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Includes 658 dividend equivalent units that had accrued on the restricted stock units.

The option vests in three equal installments on August 12, 2026, 2027 and 2028, subject to Ms. Radkoski's continued employment with the Company on the applicable vesting date.

The restricted stock units will vest in three equal installments on August 12, 2026, 2027 and 2028, subject to Ms. Radkoski's continued employment with the Company on the applicable vesting date.

The option vests in two equal installments on August 12, 2026 and 2027, subject to Ms. Radkoski's continued employment with the Company on the applicable vesting date.

The restricted stock units will vest in two equal installments on August 12, 2026 and 2027, subject to Ms. Radkoski's continued employment with the Company on the applicable vesting date.


Common Stock

Common Stock

Common Stock

Common Stock

With tandem net exercise and tax withholding rights.

The option vests in three equal installments on August 12, 2026, 2027 and 2028, subject to Ms. Esposito's continued employment with the Company on the applicable vesting date.

With tandem dividend equivalent rights and tax withholding rights.

Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.

The restricted stock units will vest in three equal installments on August 12, 2026, 2027 and 2028, subject to Ms. Esposito's continued employment with the Company on the applicable vesting date.

The option vests in two equal installments on August 12, 2026 and 2027, subject to Ms. Esposito's continued employment with the Company on the applicable vesting date.

The restricted stock units will vest in two equal installments on August 12, 2026 and 2027, subject to Ms. Esposito's continued employment with the Company on the applicable vesting date.


Common Stock

Common Stock

Common Stock

Common Stock

The option vests in three equal installments on August 12, 2026, 2027 and 2028, subject to Mr. O'Brien's continued employment with the Company on the applicable vesting date.

The restricted stock units will vest in three equal installments on August 12, 2026, 2027 and 2028, subject to Mr. O'Brien's continued employment with the Company on the applicable vesting date.

The option vests in two equal installments on August 12, 2026 and 2027, subject to Mr. O'Brien's continued employment with the Company on the applicable vesting date.

The restricted stock units will vest in two equal installments on August 12, 2026 and 2027, subject to Mr. O'Brien's continued employment with the Company on the applicable vesting date.


The price reported in column 4 is a weighted average price. These shares sold in multiple transactions at prices ranging from $57.0601 to $57.0801, inclusive. The reporting person undertakes to provide to Alaska Air Group, Inc., any security holder of Alaska Air Group, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Includes 155 shares acquired under the Alaska Air Group, Inc. Employee Stock Purchase Plan (ESPP) on April 30, 2025, in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Common shares held in  the Alaska Air Group, Inc. Employee Stock Ownership 401(k) Plan Trust, as of June 30, 2025.

/s/ Howard Kuppler, by power of attorney


As Trustee, Baileys Grandchildren's Trust FBO Jeremy Baileys

As Trustee, Baileys Grandchildren's Trust FBO Alison Brooke Baileys

Common Stock

Common Stock

Common Stock

At the effective time of the merger (the "Effective Time") between SunLink Health Systems, Inc. ("SunLink") and Regional Health Properties, Inc. ("Regional"), each five shares of Common Stock, no par value per share, of SunLink held by the Reporting Person prior to the Effective Time were converted into the right to receive (i) 1.1330 shares of Common Stock, no par value per share, of Regional, and (ii) one share of Series D 8% Cumulative Convertible Redeemable Participating Preferred Shares, no par value per share, of Regional.

This option was terminated in the merger.


Common Stock

Common Stock

Common Stock

Common Stock

The option vests in three equal installments on August 12, 2026, 2027 and 2028, subject to Mr. Spessard's continued employment with the Company on the applicable vesting date.

The restricted stock units will vest in three equal installments on August 12, 2026, 2027 and 2028, subject to Mr. Spessard's continued employment with the Company on the applicable vesting date.

The option vests in two equal installments on August 12, 2026 and 2027, subject to Mr. Spessard's continued employment with the Company on the applicable vesting date.

The restricted stock units will vest in two equal installments on August 12, 2026 and 2027, subject to Mr. Spessard's continued employment with the Company on the applicable vesting date.


These shares were sold in multiple transactions at prices ranging from $114.40 to $114.72 per share, inclusive. The holder undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Shares of Common Stock held by John P. Schauerman & Claudia H. Schauerman TR UA 08/12/10 Schauerman Family Trust.


Common Stock

Common Stock

Common Stock

Common Stock

With tandem net exercise and tax withholding rights.

The option vests in three equal installments on August 12, 2026, 2027 and 2028, subject to Mr. Min's continued employment with the Company on the applicable vesting date.

With tandem dividend equivalent rights and tax withholding rights.

Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.

The restricted stock units will vest in three equal installments on August 12, 2026, 2027 and 2028, subject to Mr. Min's continued employment with the Company on the applicable vesting date.

The option vests in two equal installments on August 12, 2026 and 2027, subject to Mr. Min's continued employment with the Company on the applicable vesting date.

The restricted stock units will vest in two equal installments on August 12, 2026 and 2027, subject to Mr. Min's continued employment with the Company on the applicable vesting date.


Common Stock

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.590 to $13.223. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

The stock option vested as to 25% of the underlying shares on July 12, 2022, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.


Includes 241.35 shares of BOKF common stock acquired under the BOKF 401(k) plan since the date of the reporting person's last ownership report.


Common Stock

Common Stock

Common Stock

Common Stock

The option vests in three equal installments on August 12, 2026, 2027 and 2028, subject to Mr. Wunsch's continued employment with the Company on the applicable vesting date.

The restricted stock units will vest in three equal installments on August 12, 2026, 2027 and 2028, subject to Mr. Wunsch's continued employment with the Company on the applicable vesting date.

The option vests in two equal installments on August 12, 2026 and 2027, subject to Mr. Wunsch's continued employment with the Company on the applicable vesting date.

The restricted stock units will vest in two equal installments on August 12, 2026 and 2027, subject to Mr. Wunsch's continued employment with the Company on the applicable vesting date.


Includes a total of 26.4960 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025.

Represents the weighted average price of the shares sold ranging from a low of $649.8492 to a high of $650.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

/s/ Lily J. Lu, Attorney-in-Fact for Michael G. Erickson


The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.53 to $97.715, inclusive. The reporting person undertakes to provide to United Airlines Holdings, Inc., any security holder of United Airlines Holdings, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.

Balance held in a revocable trust in the name of the reporting person.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.81 to $97.84, inclusive. The reporting person undertakes to provide to United Airlines Holdings, Inc., any security holder of United Airlines Holdings, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.

By spouse of the reporting person.

Balance held in a revocable trust in the name of the spouse of the reporting person.


Common Stock

Common Stock

With tandem net exercise and tax withholding rights.

The option vests in three equal installments on August 12, 2026, 2027 and 2028, subject to Mr. Suerken's continued employment with the Company on the applicable vesting date.

With tandem dividend equivalent rights and tax withholding rights.

Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.

The restricted stock units will vest in three equal installments on August 12, 2026, 2027 and 2028, subject to Mr. Suerken's continued employment with the Company on the applicable vesting date.


Common Stock

Common Stock

Common Stock

Common Stock

The option vests in three equal installments on August 12, 2026, 2027 and 2028, subject to Mr. Cook's continued employment with the Company on the applicable vesting date.

The restricted stock units will vest in three equal installments on August 12, 2026, 2027 and 2028, subject to Mr. Cook's continued employment with the Company on the applicable vesting date.

The option vests in two equal installments on August 12, 2026 and 2027, subject to Mr. Cook's continued employment with the Company on the applicable vesting date.

The restricted stock units will vest in two equal installments on August 12, 2026 and 2027, subject to Mr. Cook's continued employment with the Company on the applicable vesting date.


Class A Common Stock

Class A Common Stock

Class A Common Stock

Class A Common Stock

Class A Common Stock

Reflects shares of Class A Common Stock, shares of Class B Common Stock, or LLC Units, as applicable, held (a) directly by the Mark & Robyn Jones Descendants Trust 2014 and (b) indirectly by Mark Evan Jones and Robyn Mary Elizabeth Jones, who serve as trustees of the Mark & Robyn Jones Descendants Trust 2014 and whose immediate family members are beneficiaries of the Mark & Robyn Jones Descendants Trust 2014.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.02 to $87.01, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.02 to $88.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.02 to $88.10, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.00 to $86.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.00 to $87.97, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.00 to $88.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.00 to $89.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.27, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Reflects shares of Class A Common Stock, shares of Class B Common Stock, or LLC Units, as applicable, held directly by Mark Evan Jones, and does not reflect shares of Class A Common Stock, shares of Class B Common Stock, or LLC Units, as applicable, held by his spouse, Robyn Mary Elizabeth Jones, who is independently a reporting person of the issuer.

Reflects shares of Class A Common Stock, shares of Class B Common Stock, or LLC Units, as applicable, held directly by Robyn Mary Elizabeth Jones, and does not reflect shares of Class A Common Stock, shares of Class B Common Stock, or LLC Units, as applicable, held by her spouse, Mark Evan Jones, who is independently a reporting person of the issuer.

Reflects shares of Class B Common Stock or LLC Units, as applicable, held indirectly by Mark Evan Jones and Robyn Mary Elizabeth Jones, who serve as trustees of various trusts and whose immediate family members are beneficiaries of such trusts.

Each LLC Unit, together with a share of Class B Common Stock, may be converted by the holder into one share of Class A Common Stock at any time. The LLC Units do not expire.


The sales were executed in multiple trades at prices ranging from $453.21 to $454.20. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $463.00 to $463.96. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $464.05 to $464.70. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Shares are held by The Chen Family 2012 Irrevocable Trust, for which the Reporting Person and his spouse serve as trustees.

Certain of these securities are represented by Restricted Stock Units ("RSUs").

The sales were executed in multiple trades at prices ranging from $454.21 to $455.20. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $455.21 to $456.20. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $456.21 to $457.19. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $457.24 to $458.20. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $458.24 to $458.76. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $459.50 to $460.38. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $461.94 to $462.50. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

/s/ Victoria Valenzuela, Attorney-in-fact


The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.70 to $203.66, inclusive. The Reporting Person undertakes to provide to any security holder of Alphabet Inc. or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (8) to this Form 4.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.75 to $204.68, inclusive.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.92 to $204.93, inclusive.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.75 to $204.66, inclusive.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.81 to $204.92, inclusive.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.71 to $204.42, inclusive.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.80 to $204.81, inclusive.

The Class C Google Stock Units (GSU) entitle the Reporting Person to receive one share of Alphabet Inc. Class C Capital Stock for each share underlying the GSU as GSU vest. 1/48th of GSUs vested on July 25, 2022 and an additional 1/48th of GSUs vests on the 25th day of each month thereafter, subject to continued service on the Board on the applicable vesting dates.

1/48th of GSU grant vested on July 25, 2023 and an additional 1/48th vests monthly on the 25th day of each month thereafter, subject to continued service on the Board on the applicable vesting dates.

1/48 of GSUs will vest on the 25th day of each month following the grant date for 31 months and on the 1st day of each month for the following 17 months, subject to continued service on the Board on the applicable vesting dates.

1/48 of GSUs will vest on the 25th day of each month following the grant date for 19 months and on the 1st day of each month for the following 29 months, subject to continued service on the Board on the applicable vesting dates.

All sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the John L. Hennessy and Andrea J. Hennessy Revocable Trust UAD 10/22/93 on November 5, 2024.

/s/ Fadillah Badar, as Attorney-in-Fact for John L. Hennessy


Class A Common Stock

Class A Common Stock

Class A Common Stock

Certain of these securities are represented by Restricted Stock Units ("RSUs").

The sales were executed in multiple trades at prices ranging from $466.79 to $467.78. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $467.79 to $468.78. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $468.79 to $469.69. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $439.04 to $440.03. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $440.08 to $441.06. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $441.08 to $442.07. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $442.09 to $443.08. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $443.09 to $444.08. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $444.10 to $445.09. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $445.10 to $446.09. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $458.77 to $459.76. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $446.10 to $447.09. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $447.10 to $448.07. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $448.13 to $449.12. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $449.13 to $450.11. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $450.13 to $451.12. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $451.13 to $452.12. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $452.18 to $453.12. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Shares of Class B Common Stock are exchangeable at any time, at the option of the Reporting Person and automatically in connection with certain transfers and upon certain other events, into an equal
number of shares of Class A Common Stock.

The option is fully vested and exercisable.

The sales were executed in multiple trades at prices ranging from $459.78 to $460.77. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $460.78 to $461.71. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $461.79 to $462.78. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $462.79 to $463.78. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $463.79 to $464.78. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $464.79 to $465.78. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $465.79 to $466.78. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.


The sales were executed in multiple trades at prices ranging from $462.40 to $463.39. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Certain of these securities are represented by Restricted Stock Units ("RSUs").

The sales were executed in multiple trades at prices ranging from $463.40 to $464.38. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $464.42 to $465.41. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $465.42 to $466.415. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $466.42 to $467.41. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $467.42 to $468.41. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

The sales were executed in multiple trades at prices ranging from $468.42 to $468.895. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.


Prices ranged from $13.42 per share to $13.81 per share.


The shares were sold in multiple trades at prices ranging from $85.52 to $86.22. The price reported above reflects the weighted average sales price.

Includes 304 shares of ANI Pharmaceuticals, Inc. Common Stock that were acquired under the ANI Pharmaceuticals, Inc. Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(d) and Rule 16b-3(c).

/s/ Thomas Rowland, by attorney-in-fact Meredith W. Cook


The price reported in Column 4 is a weighted average price. The reporting person sold shares in multiple transactions at prices ranging from C$14.44 to C$14.45. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Converted from Canadian weighted average purchase price per share of C$14.4456 using an exchange rate of C$1.00 = US$0.7260, as reported by the Bank of Canada on August 12, 2025.


Common Stock

On August 12, 2025, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, in equal annual installments, beginning on February 11, 2026.

7/48 of the shares underlying the option vest on September 11, 2025, and 1/48 of the shares underlying the option vest monthly thereafter through February 11, 2029.

/s/ Todd Anderman, Attorney-in-Fact for Nadia Waheed


Shares owned directly by Ancora Catalyst. Mr. DiSanto, solely by virtue of his position as the Chairman and Chief Executive Officer of Ancora Holdings, the sole member of Ancora Alternatives, the General Partner of Ancora Catalyst, may be deemed to beneficially own the shares owned directly by Ancora Catalyst, for purposes of Section 16.Mr.DiSanto expressly disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Shares owned directly by Ancora Merlin. Mr. DiSanto, solely by virtue of his position as the Chairman and Chief Executive Officer of Ancora Holdings, the sole member of Ancora Alternatives, the General Partner of Ancora Merlin, may be deemed to beneficially own the shares owned directly by Ancora Merlin, for purposes of Section16.Mr.DiSanto expressly disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.


Common Stock, par value $0.0001 per share

/s/ Emily Fuquay, by power of attorney for John McCartney


The shares were sold in multiple trades at prices ranging from $84.40 to $87.47. The price reported above reflects the weighted average sales price.

/s/ Nikhil Lalwani, by attorney-in-fact Meredith W. Cook


At the effective time of the merger (the "Effective Time") between SunLink Health Systems, Inc. ("SunLink") and Regional Health Properties, Inc. ("Regional"), each five shares of Common Stock, no par value per share, of SunLink held by the Reporting Person prior to the Effective Time were converted into the right to receive (i) 1.1330 shares of Common Stock, no par value per share, of Regional, and (ii) one share of Series D 8% Cumulative Convertible Redeemable Participating Preferred Shares, no par value per share, of Regional.


The shares were sold in multiple trades at prices ranging from $86.50 to $86.79. The price reported above reflects the weighted average sales price.

/s/ Ori Gutwerg, by attorney-in-fact Meredith W. Cook


The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2024.


Price reflects the weighted average purchase price for the purchase transaction made on the date reported above. Purchase prices ranged from $2.26 to $2.32. The reporting person will provide, upon request by the Staff, the Company, or a security holder of the Company, full information regarding the number of shares purchased at each separate price.

Price reflects the weighted average purchase price for the purchase transaction made on the date reported above. Purchase prices ranged from $2.36 to $2.50. The reporting person will provide, upon request by the Staff, the Company, or a security holder of the Company, full information regarding the number of shares purchased at each separate price.

Price reflects the weighted average purchase price for the purchase transaction made on the date reported above. Purchase prices ranged from $2.38 to $2.46. The reporting person will provide, upon request by the Staff, the Company, or a security holder of the Company, full information regarding the number of shares purchased at each separate price


Common Stock

25% of the total options vested on each of May 6, 2017, May 6, 2018, May 6, 2019, and May 6, 2020.

/s/ Stephen P. Carey, by attorney-in-fact Meredith W. Cook


Common Stock, $.01 Par Value

Patrick J. Kinney, Jr. as attorney-in-fact for Daniel C. Croteau


The price reported is the weighted average price of multiple transactions ranging from $107.68 to $108.52. The reporting person hereby undertakes to provide upon request to the SEC, the Issuer or a security holder of the Issuer the number of shares of Common Stock and the prices at which the transactions were effected.

The reported amount consists of 1,547 restricted stock units and 84,503 shares of Common Stock. The restricted stock units are to be settled in an equal number of shares of Common Stock upon vesting.

/s/ Derek W. Stark, attorney-in-fact for Mr. Mazzella


The shares were sold in multiple trades at prices ranging from $84.50 to $87.16. The price reported above reflects the weighted average sales price.

/s/ Thomas Haughey, by attorney-in-fact Meredith W. Cook


Owned by CareVest Capital, L.L.C. ("CareVest").  Mr. Thornton owns 100% of the outstanding voting shares of CareVest and is reporting CareVest's total direct holdings of SunLink shares.

M. Timothy Elder, pursuant to a power of attorney


The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $27.81 to $28.05, inclusive. The reporting person undertakes to provide to Par Pacific Holdings, Inc. or the staff of the Securities and Exhchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.


Represents 2,627 shares of unvested restricted stock units and 7,402 shares of common stock.


Includes 33 shares reflecting the credit of dividend equivalents on outstanding RSUs and deferred stock units ("DSUs") since the reporting person's last Form 4 filing. Total reflects 9,293 DSUs held by the reporting person (including additional DSUs credited as dividend equivalents).


Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $7.44 to $7.4801. Reporting Person undertakes to provide TheRealReal, Inc., any security holder of TheRealReal, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.


The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $116.23 to $116.62, inclusive. The Reporting Person undertakes to provide to Willdan Group, Inc., any security holder of Willdan Group, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Includes (i) 1,781 shares of restricted stock that vest on June 11, 2026 and (ii) 1,124 shares of restricted stock that vest on June 12, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

/s/ Creighton K. Early, Attorney-in-fact for Steven A. Cohen


Common Stock

Common Stock

Represents a non-qualified stock option to purchase 150,000 shares of Par Pacific Holdings, Inc. ("Company") common stock at an exercise price of $21.44 per share granted to Mr. Pate on October 12, 2015, and expiring on October 11, 2025.

On August 12, 2025, the Company made a cash payment to the reporting person in an amount equal to (i) the number of shares issued to the reporting person multiplied by (ii) the the closing price of the Company's closing stock price on the New York Stock Exchange on the exercise date less (iii) the amount withheld to pay the exercise price.

Represents a non-qualified stock option to purchase 100,346 shares of Company common stock at an exercise price of $17.34 per share granted to Mr. Pate on February 27, 2018, and expiring on February 26, 2026.

The reporting person exercised the option due to the upcoming expiration date of the option and anticipated closure of the trading window under the Issuer's Insider Trading Policy prior to such date.


Represents an equity grant of common stock based on a prorated grant calculated based on $2.29, which was the closing price of the Issuer's common stock on July 29, 2025, and vests on May 15, 2026, subject to the Reporting Person's continuous service through the vesting date.

/s/ Jeff Sensiba, by power of attorney for Leonard J LeBlanc


By Daughter - Custodial Brokerage Account

By Trust - TUW RC Kemper For John Mariner

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 116.20 to 116.75, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.

/s/ Megan Mercer, attorney-in-fact for Mr. Kemper


Common Stock

Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock and Non-Voting Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement.

Prior to the Merger, the shares were held directly by Topsoe Holding A/S. Jakob Haldor Topsoe, Christina Teng Topsoe, Anne Haugwitz-Hardenberg-Reventlow, Emil Oigaard, Thomas Schleicher and Birgitte Nielsen, members of the board of directors of Topsoe Holding A/S, may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership of such shares, except to the extent of his or her pecuniary interest therein, if any.

Prior to the Merger, the shares of Non-Voting Common Stock were convertible into the Issuer's Common Stock on a 1-for-1 basis (subject to a 4.99% beneficial ownership limitation that may be increased or decreased by the holder of such shares) and had no expiration date.

/s/ Henrik Gaarn Bak, Managing Director of Topsoe Holding A/S


Represents the number of shares withheld by the Company upon the vesting of restricted shares to cover the executive's withholding tax associated with the satisfaction of all vesting conditions. The number of shares withheld is based upon the closing price of a share of Stride common stock on the vesting date, or if the vesting date fell on a weekend or market holiday, upon the closing price of a share of Stride common stock on the most recent prior market day.


Includes 10,823.1347 Restricted Stock Units that convert to Phillips 66 common stock on a 1-for-1 basis.

/s/ William H. Bald, as Attorney-in-Fact


Common Stock


Common Stock

Prior to the Merger, the shares were held by Pillarcater LLC. The Reporting Person is the sole manager of Pillarcater LLC, which is wholly owned by CT Foundation (a South Dakota Trust) of which the Reporting Person is the sole beneficiary.


Common Shares

Common Shares

Common Shares

Common Shares

Common Shares

Common

Reporting person sold Common Shares at an average price of $39.02135 of which the Common Shares were sold in multiple transactions at prices ranging from $39.00 and $39.0263. The reporting person undertakes to provide to the SEC, the Issuer and any security holder, the full information regarding the number of shares and the prices at which the shares were sold.

Reporting person sold Common Shares at an average price of $39.155 of which the Common Shares were sold in multiple transactions at prices ranging from $39.10 and $39.21. The reporting person undertakes to provide to the SEC, the Issuer and any security holder, the full information regarding the number of shares and the prices at which the shares were sold.

Granted under the Long-Term Incentive Plan.  Option was exercisable.


/s/ Kathy Card Beckles, Attorney-in-fact


Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement.


Common Stock

Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $0.4076 to $0.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.


Common Stock

/s/ Robin H. Cowie as Attorney-in-Fact for Scott Hutton


Common Stock

/s/ Robin H. Cowie as Attorney-in-Fact for Kieran O'Kane


Common Stock

/s/ Robin H. Cowie as Attorney-in-Fact for Gary Pestano


Common Stock

/s/ Robin H. Cowie as Attorney-in-Fact for Chris Vazquez


This transaction was executed in multiple trades at prices ranging from $146.96 to $147.30, inclusive. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) of this Form 4.

This transaction was executed in multiple trades at prices ranging from $149.93 to $150.54, inclusive. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4.

This transaction was executed in multiple trades at prices ranging from $151.03 to $152.01, inclusive. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4.

This transaction was executed in multiple trades at prices ranging from $152.085 to $153.07, inclusive. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4.

This transaction was executed in multiple trades at prices ranging from $153.10 to $154.095, inclusive. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) of this Form 4.

This transaction was executed in multiple trades at prices ranging from $154.1 to $154.58, inclusive. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) of this Form 4.

This transaction was executed in multiple trades at prices ranging from $155.14 to $156.13, inclusive. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) of this Form 4.

This transaction was executed in multiple trades at prices ranging from $156.14 to $157.115, inclusive. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range set forth in footnote (8) of this Form 4.

This transaction was executed in multiple trades at prices ranging from $157.175 to $157.18, inclusive. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range set forth in footnote (9) of this Form 4.

Charlotte Montressor Willis.

Wilder Grace Willis 2016 Trust.


Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock, and each outstanding RSU, was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement.


This number represents shares acquired upon vesting of performance-based restricted share units ("PSUs") granted on August 24, 2023, as a result of exceeding pre-established performance targets that were certified by the Compensation Committee of the Issuer on August 12, 2025.

The reported shares were withheld to cover the Reporting Person's tax liability in connection with the vesting of PSUs.

Andrew Chew, Attorney-in-fact for Edward T. Archer


American Depositary Shares

American Depositary Shares

Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2024.

Reflects a weighted average sale price of $34.2511 per share, at prices ranging from $33.70 to $34.60 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Reflects a weighted average sale price of $35.4687 per share, at prices ranging from $34.845 to $35.80 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

The Stock Options fully vested as of October 22, 2020.


Common Stock

Common Stock

The shares underlying the option shall vest in 36 equal monthly installments commencing on September 12, 2025, subject to the Reporting Person's continuous service through each vesting date.

The derivative securities were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.

1,383 shares underlying the option shall vest on September 30, 2025, and 2,545 shares underlying the option shall vest on December 31, 2025, subject to the Reporting Person's continuous service through each such vesting date.

This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $8,682.07.


Andrew Chew, Attorney-in-fact for Csaba Sverha


On August 13, 2025, the Issuer granted the Reporting Person a restricted stock award of 250,000 shares of Issuer Common Stock pursuant to Issuer's 2021 Management Incentive Plan. The award will vest in four equal annual installments commencing on August 13, 2026, subject to the Reporting Person's continued employment through each such vesting date or earlier vesting upon a change-of-control as well as, in the event of termination without cause or for good reason, accelerated vesting of the next two tranches, if applicable.

Exhibit 24 Limited Power of Attorney filed with Form 3 dated August 13, 2025, which was filed on August 14, 2025.

/s/ J. Bryant Kirkland III, Attorney-in-Fact for Bradley H. Brodie


Andrew Chew, Attorney-in-fact for Harpal Gill


Class A Common Stock

Each Class B unit of NuScale Power, LLC, an Oregon limited liability company and a wholly owned subsidiary of the Issuer ("Class B Units"), together with one share of Class B common stock, par value $0.0001 per share, of the Issuer ("Class B Common Stock"), is exchangeable into one share of Class A common stock, par value $0.0001 per share, of the Issuer ("Class A Common Stock") with no expiration date.

15,000,000 shares of Class A Common Stock, 110,936,472 Class B Units and 110,936,472 shares of Class B Common Stock are owned of record by Fluor Enterprises, Inc., which is a wholly owned subsidiary of Fluor Corporation, whose principal business address is 6700 Las Colinas Boulevard, Irving, Texas 75039.  463,747 Class B Units and 463,747 shares of Class B Common Stock are owned of record by NuScale Holdings Corp., which is majority owned by Fluor Enterprises, Inc.

/s/ Kevin B. Hammonds, Executive Vice President, Chief Legal Officer and Corporate Secretary


Common Stock Par Value $0.10 Per Share

Restricted stock units convert into common stock on a one-for-one basis.

The 693 reflected on this table represents the shares withheld to pay the Reporting Person's federal, state, and Federal Insurance Contributions Act ("FICA") tax.

This transaction represents the vesting of 1,374 of the 4,123 restricted stock units issued to the Reporting Person on August 12, 2022.

/s/ Michael C. Shay, Attorney-in-Fact for Daniel Gizinski


Common Stock Par Value $.10 Per Share

The 2,472 reflected on this table represents the shares withheld to pay the Reporting Person's federal, state, and Federal Insurance Contributions Act ("FICA") tax.

This transaction represents the vesting of 4,842 of the 14,527 restricted stock units issued to the Reporting Person on August 12, 2022.

/s/ Michael C. Shay, Attorney-in-Fact for Michael Bondi


This number represents shares acquired upon vesting of performance-based restricted share units ("PSUs") granted on August 24, 2023, as a result of exceeding pre-established performance targets that were certified by the Compensation Committee of the Issuer on August 12, 2025.

The reported shares were withheld to cover the Reporting Person's tax liability in connection with the vesting of PSUs.

Andrew Chew, Attorney-in-fact for Seamus Grady


This transaction was executed in multiple trades at prices ranging from $14.75 USD to $15.00 USD; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes, upon request, to provide to Comstock Holding Companies, Inc. (the "Issuer"), any security holder ofthe Issuer, or the Securities and Exchange Commission, full information regarding the number of shares and prices at which the transaction was effected.


The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.12, inclusive. The reporting person undertakes to provide to Bridgewater Bancshares, Inc., any security holder of Bridgewater Bancshares, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price set forth in this footnote to this Form 4.


Baker Alexander James

WELLESLEY HOUSE NORTH, 90 PITTS BAY ROAD

The price reported in Column 4 represents a weighted average price. These Class B common shares were sold in multiple transactions at prices ranging from $23.75 to $23.81, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.


Restricted stock units granted pursuant to the Granite Construction Incorporated 2024 Equity Incentive Plan. Restricted stock units vest on May 20, 2026.

Total adjusted to include dividend equivalents (DEUs: 18 - 7/15/24; 14 - 10/15/24; 13 - 1/15/25; 15 - 4/15/25; 9 - 7/15/25) credited to the Reporting Person under the dividend reinvestment feature of the Granite Construction Incorporated equity plans since the Reporting Person's last report.

/s/ Troy Erickson, attorney-in-fact for Louis E. Caldera


Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement.

Prior to the Merger, the shares were held in the name of KBW 2005 Trust for which Reporting Person is the Trustee.

Prior to the Merger, the shares were held in the name of Non-Exempt Trust for Patrick R. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee.

Prior to the Merger, the shares were held in the name of Non-Exempt Trust for Shannon K. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee.


Total adjusted to include dividend equivalents (DEUs: 8 - 4/15/25; 4 - 7/15/25) credited to the Reporting Person under the dividend reinvestment feature of the Granite Construction Incorporated equity plans since the Reporting Person's last report.

/s/ Troy Erickson, attorney-in-fact for Molly C. Campbell


/s/ Troy Erickson, attorney-in-fact for Alan P. Krusi


Total adjusted to include dividend equivalents (DEUs: 3 - 1/15/25; 3 - 4/15/25) credited to the Reporting Person under the dividend reinvestment feature of the Granite Construction Incorporated equity plans since the Reporting Person's last report.

/s/ Troy Erickson, attorney-in-fact for Celeste B. Mastin


CAROLINE A. WINN BY: Lisa H. Abbot, Managing Attorney - Corporate and Securities of Sempra and Attorney-In-Fact


Total adjusted to include dividend equivalents (DEUs: 18 - 7/15/24; 14 - 10/15/24; 13 - 1/15/25; 15 - 4/15/25; 13 - 7/15/25) credited to the Reporting Person under the dividend reinvestment feature of the Granite Construction Incorporated equity plans since the Reporting Person's last report.

/s/ Troy Erickson, attorney-in-fact for Laura M. Mullen


Total adjusted to include dividend equivalents (DEUs: 60 - 7/15/24; 46 - 10/15/24; 41 - 1/15/25; 49 - 4/15/25; 40 - 7/15/25) credited to the Reporting Person under the dividend reinvestment feature of the Granite Construction Incorporated equity plans since the Reporting Person's last report.

/s/ Troy Erickson, attorney-in-fact for Michael F. McNally


Total adjusted to include dividend equivalents (DEUs: 4 - 7/15/24; 3 - 10/15/24; 3 - 1/15/25; 3 - 4/15/25) credited to the Reporting Person under the dividend reinvestment feature of the Granite Construction Incorporated equity plans since the Reporting Person's last report.

/s/ Troy Erickson, attorney-in-fact for Carlos M. Hernandez


MOORTHY GANESH

4000 CENTER AT NORTH HILLS ST, SUITE 430

The price reported in Column 4 is a weighted average price rounded to the nearest hundredth. These shares were purchased in two separate transactions with 1,000 shares purchased at $45.33 and 1,000 shares purchased at $45.00.


common shares

Represents the conversion upon exercise of stock options into common shares.

These options were issued in 2019 and are set to expire on March 7, 2026.

The stock options became exercisable in four installments: 1,414 on March 7, 2020, 1,768 on each of March 7, 2021 and March 7, 2022, and 2,122 on March 7, 2023.

This represents the number of restricted share units for this transaction only. Mr. Weissman's aggregate remaining outstanding restricted share unit and common share balances following these transactions will be 17,021 and 26,133. respectively.


Includes 2,566 unvested Restricted Stock Units ("RSUs") acquired pursuant to an original grant of 2,522 RSUs and shares acquired through automatic dividend reinvestment, vesting 2/24/2026, the first anniversary of the grant.

The reporting person's receipt of certain shares underlying vested RSUs and related shares acquired through automatic dividend reinvestment have been deferred.

/s/ Stacy S. Rust, attorney-in-fact for Margaret M. McCarthy